I don’t know enough about it to have an educated opinion. The company does seem to be below the radar screen of many biotech investors; perhaps this is because it doesn’t trade on a US exchange.
I had posted something (little) on them probably a couple years ago if you have search. I don't recall much but there was a good analysts report or article I read that talked about how the drug was supposed to work and didn't like its chances which discouraged me from seriously considering it. I kept watching them though but never close to buying.
I do remember one of the founders wife had MS and that is how they got the company started. They also would buy back then do an offering buy back a little more do an offering. I thought they were playing games and didn't like that either.
The Lilly (?) deal probably gave them credibility but still I believe they only recently licensed a second compound so if it fails the stock will (in todays market) go well below cash.
Market Data 
Markets 
AI
